Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
← catalyst calendarSponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →. With Bristol-Myers Squibb.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
0actual
Sites
34
Countries
Czechia, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-30 | estimated | When the study began enrolling |
| Primary completion | 2026-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Squamous Cell Carcinoma of Head and Neck
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
- Biological: RP3
- Other: CCRT(concurrent chemoradiation therapy)
- Other: carboplatin and paclitaxel
- Biological: nivolumab
Primary outcomes
what the primary-completion date above is the date OFLA Cohort: Progression-free Survival
measured From Day 1 to documented progression of disease (up to 3 years)
R/M Cohort: Objective Response Rate
measured From Day 1 to documented progression of disease (up to 3 years)
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed